Drug Pipeline

Mitigation of Viral Infection (HIV, Coronavirus): At Viron Therapeutics, we have developed a VIRONTM Membrane Virus Prevention (mVIRP) formulation (patent submitted) to mitigate infection by enveloped viruses, such as HIV and Coronavirus. The active constituent used in this water-based formulation is a U.S. Food and Drug Administration (FDA) approved product, which is currently in use in over 40 pharmaceutical drugs, administered either via oral, nasal, pulmonary, ocular, anal or dermal routes. The proposed effective dose of the active constituent in the formulation to be administered falls within the FDA-specified guidelines. The proposed route of administration of the formulation is dermal, nasal and pulmonary, using a soft mist inhaler to deliver a precise dose. The formulation is engineered to remain sterile in presence of benzalkonium chloride, commonly used in nasal, inhalable, ophthalmic and topical preparations in current use. The formulation has the additional potential of mitigating bacterial and fungal infections.  In addition to having a potential in mitigating the actual Covid-19 crisis, VIRONTM mVIRP formulation holds great promise for its use by health care providers. We believe that, the challenge of overcoming infection by a mutated enveloped virus, such as Coronavirus and HIV, can be addressed, at least in part, using the VIRONTM mVIRP formulation.

FDA = U.S. Food and Drug Administration; EUA = Emergency Use Authorization.


Lead Asset

Viron has established partnerships with the Viron Molecular Medicine Institute (MMI), Boston, MA, USA International Vaccine Institute, Seoul, Korea, and collaborates with both US research institutions and the Joint Clinical Research Center, to conduct advanced Clinical Trials on the VIRONTM mVIRP formulation (FDA-approved active compound) to mitigate infection by enveloped viruses, such as HIV/AIDS, Coronavirus/COVID-19, influenza and hepatitis viruses.